Jasper Therapeutics Inc. (JSPR)

The total asset value of Jasper Therapeutics Inc. (JSPR) stood at $ 122 Mln as on 30-Sep-23

The share price of Jasper Therapeutics Inc. (JSPR) is $0.50 (NASDAQ) as of 11-Dec-2023 09:45 EST. Jasper Therapeutics Inc. (JSPR) has given a return of -63.09% in the last 3 years.

Jasper Therapeutics Inc. (JSPR) has a market capitalisation of $ 57 Mln as on 08-Dec-2023. As per Value Research classification, it is a Small Cap company.

The P/B ratio of Jasper Therapeutics Inc. (JSPR) is 0.60 times as on 08-Dec-2023, a -0.76% premium to its peers’ median range of 2.54 times.

Since, TTM earnings of Jasper Therapeutics Inc. (JSPR) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Jasper Therapeutics Inc. (JSPR) and enter the required number of quantities and click on buy to purchase the shares of Jasper Therapeutics Inc. (JSPR).

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.

The CEO & director of Dr. Judith Anne Shizuru M.D., Ph.D.. is Jasper Therapeutics Inc. (JSPR), and CFO & Sr. VP is Mr. Jeetinder Singh Mahal M.B.A..

The promoters of Jasper Therapeutics Inc. (JSPR) have pledged 0% of the total equity as on Jun-23.

Some of the close peers are:

No, TTM profit after tax of Jasper Therapeutics Inc. (JSPR) was $-44 Mln.